About citius pharmaceuticals inc - CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.
CTXR At a Glance
Citius Pharmaceuticals, Inc.
11 Commerce Drive
Cranford, New Jersey 07016
| Phone | 1-908-967-6677 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -37,433,911.00 | |
| Sector | Health Technology | Employees | 23 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
CTXR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.332 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.555 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.085 |
CTXR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,627,561.348 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CTXR Liquidity
| Current Ratio | 0.622 |
| Quick Ratio | 0.126 |
| Cash Ratio | 0.095 |
CTXR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -30.211 |
| Return on Equity | -54.399 |
| Return on Total Capital | -53.968 |
| Return on Invested Capital | -54.105 |
CTXR Capital Structure
| Total Debt to Total Equity | 2.684 |
| Total Debt to Total Capital | 2.614 |
| Total Debt to Total Assets | 1.382 |
| Long-Term Debt to Equity | 1.073 |
| Long-Term Debt to Total Capital | 1.045 |